{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T08:39:03.568395+00:00","company":{"ticker":"IRMD","cik":1325618,"company_name":"IRADIMED CORP"},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"eedf8bb42dd11e31773597044a01f176fc08c4e9","cik":1325618,"ticker":"IRMD","company_name":"IRADIMED CORP","filed_at":"2026-05-01T23:59:59+00:00","payload":{"eps_text":"$0.45 per diluted share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"net income of $5.8 million","period_text":"first quarter of 2026","report_date":"2026-05-01","result_type":"reported_results","revenue_text":"revenue of $22.0 million"},"claim":"IRADIMED CORP reported first quarter of 2026 results: revenue revenue of $22.0 million, net income net income of $5.8 million, EPS $0.45 per diluted share. Guidance reaffirmed.","evidence_excerpt":"IRADIMED CORPORATION Reports First Quarter 2026 Financial Results Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance • Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025. • Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001628280-26-029125","anchor_url":"https://secwatch.observer/filing/0001628280-26-029125#claim-eedf8bb42dd11e31773597044a01f176fc08c4e9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1325618/000162828026029125/0001628280-26-029125-index.htm"},{"fact_type":"earnings_release","fact_key":"6daf4caee254baddaec40fa233450a309d56b586","cik":1325618,"ticker":"IRMD","company_name":"IRADIMED CORP","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":"$0.32 per diluted share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$4.1 million","period_text":"the three months ended March 31, 2024","report_date":"2024-05-02","result_type":"reported_results","revenue_text":"$17.6 million"},"claim":"IRADIMED CORP reported the three months ended March 31, 2024 results: revenue $17.6 million, net income $4.1 million, EPS $0.32 per diluted share. Guidance reaffirmed.","evidence_excerpt":"IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share ● Reports record revenue of $17.6 million for the first quarter of 2024. ​ ● Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the first quarter of 2024. ​ ● Reports first quarter of 2024 operating","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-006460","anchor_url":"https://secwatch.observer/filing/0001558370-24-006460#claim-6daf4caee254baddaec40fa233450a309d56b586","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1325618/000155837024006460/0001558370-24-006460-index.htm"}]}